The stock may react positively to the 2026 growth guidance and cost savings plan, but investors should monitor the execution of the restructuring, resolution of the India manufacturing issues, and whether the recent quarterly revenue improvement can be sustained to reverse the full-year decline trend.
Drugs in focus
VTRS drug pipeline →norelgestromin/ethinyl estradiol weekly patch
● Neutral Named in this 8-K- Impact
- Phase
- Filed/PDUFA
- Time to market
- Approved product (Xulane) already on market since 2014. XULANE LO (low-dose version) PDUFA decision July 30, 2026 — potential launch H2 2026 if approved.
- Next catalyst
- None dated
What to watchWatch the July 30, 2026 PDUFA date for XULANE LO. If approved, the low-estrogen positioning and "best-in-class adhesion" claims could help Viatris capture share in the ~$1B+ contraceptive patch market. A CRL (complete response letter) would be a near-term negative but not company-threatening given Viatris's diversified portfolio. The stock is near its 52-week high (~$17.53) with 12 sell-side analysts averaging a $17.81 target, suggesting modest upside is already priced in.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $15.12entry
- T+1 · 9mo ago −2.10%α −1.65% · $14.80
- T+5 · 9mo ago −4.72%α −3.59% · $14.41
- T+20 · 8mo ago −11.58%α −5.18% · $13.37
- T+60 · 6mo ago +8.86%α +1.11% · $16.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Viatris reported mixed financial results for 2025, with full-year revenue declining 3% YoY but fourth-quarter revenue growing 5% YoY. The company announced a major restructuring expected to incur $700M-$850M in charges to achieve $650M in cost savings, while also revealing a fire at its Nashik, India manufacturing facility. Despite the operational challenges, management provided 2026 guidance projecting revenue growth to $14.45B-$14.95B and positioned the company for a turnaround.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue declined 3% YoY to $14.3B, with generics revenue down 8% and brands revenue flat
- Fourth-quarter revenue grew 5% YoY to $3.7B, showing recent improvement
- Company announced restructuring with $700M-$850M in charges to achieve $650M in cost savings
- Fire at Nashik, India manufacturing facility temporarily suspended operations with expected resumption in April 2026
- 2026 guidance projects revenue of $14.45B-$14.95B and adjusted EPS of $2.33-$2.47
- Adjusted EPS declined 11% YoY to $2.35 in 2025
Financial Impact
Restructuring charges of $700M-$850M expected to yield $650M in cost savings; 2026 revenue guidance of $14.45B-$14.95B represents 1-5% growth over 2025
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Brands | $9.2B | -0.2% |
| Generics | $5.1B | -7.7% |
Risk Factors
- Execution risk on the major restructuring plan
- Ongoing manufacturing issues at India facilities impacting supply
- Declining generics business (-8% YoY) and flat brands revenue
- High debt levels with $12.5B in long-term debt
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001792044-26-000010 |
| Document: vtrs-20260223.htm | 0001792044-26-000010 |
| Document: 0001792044-26-000010-index-headers.html | 0001792044-26-000010 |
| Document: 0001792044-26-000010-index.html | 0001792044-26-000010 |
| Document: 0001792044-26-000010.txt | 0001792044-26-000010 |
Track record
22 reports on VTRS
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +16.85% at T+60 after the Aug 6, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers